One interesting previous case law is the Integra case, where the defendant did not use the patented products for making substitution pharmaceutical but as research tools to develop a new drug in a preclinical trial and data was not even submitted in the IND to the FDA. Would you think the Bolar Exception apply in such act? Read The Supreme Court ruling.
Market Data 
Markets 
AI
